What does Santhera Pharmaceuticals do?

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company founded in 2004 and based in Pratteln, Switzerland. The company focuses on developing and commercializing innovative medicines for rare neuromuscular and pulmonary diseases, addressing significant unmet medical needs in Europe, North America, and Asia. With a commitment to improving patients' quality of life, Santhera emphasizes treatments for conditions like Duchenne muscular dystrophy (DMD). The company's lead candidate, Vamorolone, is a dissociative steroid currently under review by regulatory authorities, including the FDA and EMA, for the treatment of DMD. Additionally, Santhera is advancing Lonodelestat, which is in Phase 2a studies for cystic fibrosis and other acute pulmonary conditions. The company is positioned to explore partnerships for further development and licensing of its promising therapies.